Literature DB >> 17165074

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy.

Peter Lindgren1, Thomas Kahan, Neil Poulter, Martin Buxton, Patrick Svarvar, Björn Dahlöf, Bengt Jonsson.   

Abstract

This study assessed the loss of utility and indirect costs associated with first cardiovascular events. Data was collected (using EQ-5D) prospectively at 3, 6, and 12 months following an event in the Swedish part of the Anglo-Scandinavian cardiac outcomes trial (ASCOT), including patients with mild to moderate hypertension and additional risk factors. Sixty patients were eligible for analysis. An event was associated with a one-year utility loss of 0.075 (95% CI: 0.038-0.114). For a stroke, the reduction was 0.145 (CI: 0.059-0.249) and for acute coronary syndromes (myocardial infarction or unstable angina) the loss was 0.051 (-0.003 to 0.103). The utility at baseline was no different to the utility in a control group. The indirect cost over the first 12 months (2003 Swedish Kronor, SEK) was 90028 SEK (CI: 46027-146754), 9866 euro for patients in the workforce. These results are helpful in future economic evaluations of primary preventive measures in cardiovascular medicine.

Entities:  

Mesh:

Year:  2007        PMID: 17165074     DOI: 10.1007/s10198-006-0002-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  15 in total

1.  Swedish population health-related quality of life results using the EQ-5D.

Authors:  K Burström; M Johannesson; F Diderichsen
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

Review 3.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.

Authors:  P S Sever; B Dahlöf; N R Poulter; H Wedel; G Beevers; M Caulfield; R Collins; S E Kjeldsen; G T McInnes; J Mehlsen; M Nieminen; E O'Brien; J Ostergren
Journal:  J Hypertens       Date:  2001-06       Impact factor: 4.844

6.  Costs of coronary heart disease and stroke: the case of Sweden.

Authors:  N Zethraeus; T Molin; P Henriksson; B Jönsson
Journal:  J Intern Med       Date:  1999-08       Impact factor: 8.989

7.  Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Authors:  Peter Lindgren; Martin Buxton; Thomas Kahan; Neil R Poulter; Björn Dahlöf; Peter S Sever; Hans Wedel; Bengt Jönsson
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2005-02

8.  Stability of time-tradeoff utilities in survivors of myocardial infarction.

Authors:  J Tsevat; L Goldman; J R Soukup; G A Lamas; K F Connors; C C Chapin; T H Lee
Journal:  Med Decis Making       Date:  1993 Apr-Jun       Impact factor: 2.583

9.  Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction.

Authors:  N Oldridge; W Furlong; D Feeny; G Torrance; G Guyatt; J Crowe; N Jones
Journal:  Am J Cardiol       Date:  1993-07-15       Impact factor: 2.778

10.  Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Authors:  Philip Clarke; Alastair Gray; Rury Holman
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583

View more
  14 in total

Review 1.  Cost-effectiveness of statins revisited: lessons learned about the value of innovation.

Authors:  Peter Lindgren; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04-29

2.  Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).

Authors:  Rachel A Elliott; Koen D Putman; Matthew Franklin; Lieven Annemans; Nick Verhaeghe; Martin Eden; Jasdeep Hayre; Sarah Rodgers; Aziz Sheikh; Anthony J Avery
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

3.  Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.

Authors:  Abdullah Pandor; Daniel Horner; Sarah Davis; Steve Goodacre; John W Stevens; Mark Clowes; Beverley J Hunt; Tim Nokes; Jonathan Keenan; Kerstin de Wit
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

4.  Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.

Authors:  Jonas Nilsson; Örjan Åkerborg; Gaëlle Bégo-Le Bagousse; Mårten Rosenquist; Peter Lindgren
Journal:  Eur J Health Econ       Date:  2012-05-03

5.  The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Authors:  Peter Lindgren; Martin Buxton; Thomas Kahan; Neil R Poulter; Björn Dahlöf; Peter S Sever; Hans Wedel; Bengt Jönsson
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Revisiting rose: comparing the benefits and costs of population-wide and targeted interventions.

Authors:  Jennifer Ahern; Matthew R Jones; Erin Bakshis; Sandro Galea
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

7.  Economic evaluation of plerixafor for stem cell mobilization.

Authors:  Steven M Kymes; Iskra Pusic; Dennis L Lambert; Martin Gregory; Kenneth R Carson; John F DiPersio
Journal:  Am J Manag Care       Date:  2012-01       Impact factor: 2.229

8.  Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.

Authors:  Ola Granström; Lars-Åke Levin; Martin Henriksson
Journal:  Clinicoecon Outcomes Res       Date:  2012-11-01

Review 9.  A review of health utilities using the EQ-5D in studies of cardiovascular disease.

Authors:  Matthew T D Dyer; Kimberley A Goldsmith; Linda S Sharples; Martin J Buxton
Journal:  Health Qual Life Outcomes       Date:  2010-01-28       Impact factor: 3.186

10.  Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.

Authors:  Matthew R Reynolds; Jonas Nilsson; Orjan Akerborg; Mehul Jhaveri; Peter Lindgren
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.